Nasdaq · CIK 0002100782
GENB Generate Biomedicines, Inc.
Insider trading from SEC Form 4. Last filing 40 d ago. Close $14.34 on Oct 9, 2026, +28% from the 52-week low and -30% from the high.
In brief
Generate Biomedicines, Inc. (GENB) has 17 SEC Form 4 filings on file from 14 insiders, the latest filed on Sep 3, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 1 open-market sell worth $16k, net -$16k.
7 open-market trades have been scored at GENB. The newest: Frances Arnold (director) sold $16k of stock on Sep 1, 2026, filed Sep 3, 2026, scored 0 (weak), under a 10b5-1 plan. The largest of the 7 shown: Noubar Afeyan (director and 10% owner) bought $75M on Mar 2, 2026, scored 71 (notable). 5 insiders bought within 14 days of each other around Mar 4, 2026.
2 Form 144 notices of planned sales are on file, the latest filed Sep 2, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Generate Biomedicines, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Frances Arnold director sell | $16k 1,000 shares | -0% | - | |
| 63Notable | Michael Nally Chief Executive Officer buy | $240k 20,000 shares | +4% | 0% from low-8% from high | |
| 71Notable | Noubar Afeyan director, owner buy | $75M 4,687,500 shares | +34% | 0% from low-4% from high | |
| 71Notable | Noubar Afeyan director, owner buy | $75M 4,687,500 shares | +34% | 0% from low-4% from high | |
| 48Moderate | Jane L Mendillo director buy | $24k 1,500 shares | - | 0% from low-4% from high | |
| 60Notable | Jason Silvers President & CFO buy | $32k 2,000 shares | - | 0% from low-4% from high | |
| 48Moderate | Beth Grous Chief People Officer buy | $4,800 300 shares | - | 0% from low-4% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 2, 2026 | ARNOLD FRANCES Director | 32,210 0.03% of outstanding | $521k | Sep 2, 2026 | $16k |
| Sep 1, 2026 | ARNOLD FRANCES Director | 1,000 0.00% of outstanding | $16k | Sep 1, 2026 | none |
Transactions
The newest 50 of 65 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Frances Arnold director | SOpen-market sale Common Stock10b5-1 | -1,000 | $16.00 | $16k | 231,472 | 40 d ago |
| Mar 4, 2026 | Michael Nally Chief Executive Officer | POpen-market purchase Common Stock | +20,000 | $12.00 | $240k | 572,707 | Mar 6, 2026 |
| Mar 2, 2026 | Jane L Mendillo director | POpen-market purchase Common Stock | +1,500 | $16.00 | $24k | 1,500 | Mar 2, 2026 |
| Mar 2, 2026 | Stephane Bancel director | CConversion Common Stockindirect: By OCHA LLC | +724,160 | - | - | 724,160 | Mar 2, 2026 |
| Feb 26, 2026 | Paul Gray Parker director | AGrant or award Stock Option (Right to Buy)derivative | +29,561 | $0.00 | $0 | 29,561 | Mar 2, 2026 |
| Feb 26, 2026 | Marsha Fanucci director | AGrant or award Stock Option (Right to Buy)derivative | +29,561 | $0.00 | $0 | 29,561 | Mar 2, 2026 |
| Feb 26, 2026 | Frances Arnold director | AGrant or award Stock Option (Right to Buy)derivative | +29,561 | $0.00 | $0 | 29,561 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Common Stockindirect: By Flagship Pioneering Fund VI, L.P. | +12,723,940 | - | - | 12,723,940 | Mar 2, 2026 |
| Feb 26, 2026 | Gevorg Grigoryan Chief Technology Officer | AGrant or award Stock Option (Right to Buy)derivative | +295,608 | $0.00 | $0 | 295,608 | Mar 2, 2026 |
| Feb 26, 2026 | Laurie Anne Lee Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +42,230 | $0.00 | $0 | 42,230 | Mar 2, 2026 |
| Mar 2, 2026 | Jason Silvers President & CFO | POpen-market purchase Common Stockindirect: By daughter | +500 | $16.00 | $8,000 | 500 | Mar 2, 2026 |
| Feb 26, 2026 | Sean Martin Chief Legal Officer & GC | AGrant or award Stock Option (Right to Buy)derivative | +190,034 | $0.00 | $0 | 190,034 | Mar 2, 2026 |
| Feb 26, 2026 | Rupert Vessey director | AGrant or award Stock Option (Right to Buy)derivative | +29,561 | $0.00 | $0 | 29,561 | Mar 2, 2026 |
| Mar 2, 2026 | Beth Grous Chief People Officer | POpen-market purchase Common Stockindirect: By Spouse | +300 | $16.00 | $4,800 | 300 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Common Stockindirect: By Flagship Pioneering Fund VI, L.P. | +12,723,940 | - | - | 12,723,940 | Mar 2, 2026 |
| Mar 2, 2026 | Michael Nally Chief Executive Officer | CConversion Common Stockindirect: By MTN 2024 GST Trust | +658,327 | - | - | 1,316,654 | Mar 2, 2026 |
| Feb 26, 2026 | Nancy A Simonian director | AGrant or award Stock Option (Right to Buy)derivative | +29,561 | $0.00 | $0 | 29,561 | Mar 2, 2026 |
| Feb 26, 2026 | Gevorg Grigoryan Chief Technology Officer | AGrant or award Stock Option (Right to Buy)derivative | +196,368 | $0.00 | $0 | 196,368 | Mar 2, 2026 |
| Feb 26, 2026 | Jane L Mendillo director | AGrant or award Stock Option (Right to Buy)derivative | +29,561 | $0.00 | $0 | 29,561 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Common Stockindirect: By Flagship Pioneering Fund VII, L.P. | +13,702,224 | - | - | 13,702,224 | Mar 2, 2026 |
| Mar 2, 2026 | Jason Silvers President & CFO | POpen-market purchase Common Stockindirect: By daughter | +500 | $16.00 | $8,000 | 500 | Mar 2, 2026 |
| Feb 26, 2026 | Beth Grous Chief People Officer | AGrant or award Stock Option (Right to Buy)derivative | +114,020 | $0.00 | $0 | 114,020 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Common Stockindirect: By Flagship Pioneering Fund VII, L.P. | +13,702,224 | - | - | 13,702,224 | Mar 2, 2026 |
| Feb 26, 2026 | Stephane Bancel director | AGrant or award Stock Option (Right to Buy)derivative | +29,561 | $0.00 | $0 | 29,561 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Common Stockindirect: By Nutritional Health LTP Fund, L.P. | +987,491 | - | - | 987,491 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Common Stockindirect: By Nutritional Health LTP Fund, L.P. | +987,491 | - | - | 987,491 | Mar 2, 2026 |
| Mar 2, 2026 | Jason Silvers President & CFO | POpen-market purchase Common Stockindirect: By son | +1,000 | $16.00 | $16k | 1,000 | Mar 2, 2026 |
| Feb 26, 2026 | Michael Nally Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +844,595 | $0.00 | $0 | 844,595 | Mar 2, 2026 |
| Mar 2, 2026 | Stephane Bancel director | CConversion Series A Preferred Stockderivativeindirect: By OCHA LLC | -1,100,000 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Common Stockindirect: By Flagship Pioneering Special Opportunities Fund II, L.P. | +2,777,752 | - | - | 2,777,752 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Common Stockindirect: By Flagship Pioneering Special Opportunities Fund II, L.P. | +2,777,752 | - | - | 2,777,752 | Mar 2, 2026 |
| Feb 26, 2026 | Jason Silvers President & CFO | AGrant or award Stock Option (Right to Buy)derivative | +295,608 | $0.00 | $0 | 295,608 | Mar 2, 2026 |
| Feb 26, 2026 | Michael Nally Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +844,595 | $0.00 | $0 | 844,595 | Mar 2, 2026 |
| Feb 26, 2026 | Jason Silvers President & CFO | AGrant or award Stock Option (Right to Buy)derivative | +274,493 | $0.00 | $0 | 274,493 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Common Stockindirect: By FPN II, L.P. | +2,777,752 | - | - | 2,777,752 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Common Stockindirect: By FPN II, L.P. | +2,777,752 | - | - | 2,777,752 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | POpen-market purchase Common Stockindirect: By Flagship Pioneering Fund VII, L.P. | +1,562,500 | $16.00 | $25M | 15,264,724 | Mar 2, 2026 |
| Mar 2, 2026 | Michael Nally Chief Executive Officer | CConversion Series A Preferred Stockderivativeindirect: By MTN 2024 GST Trust | -1,000,000 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | POpen-market purchase Common Stockindirect: By Flagship Pioneering Fund VII, L.P. | +1,562,500 | $16.00 | $25M | 15,264,724 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | POpen-market purchase Common Stockindirect: By FPN II, L.P. | +1,562,500 | $16.00 | $25M | 4,340,252 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | POpen-market purchase Common Stockindirect: By FPN II, L.P. | +1,562,500 | $16.00 | $25M | 4,340,252 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | POpen-market purchase Common Stockindirect: By Pioneering Medicines 02, LLC | +1,562,500 | $16.00 | $25M | 1,562,500 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | POpen-market purchase Common Stockindirect: By Pioneering Medicines 02, LLC | +1,562,500 | $16.00 | $25M | 1,562,500 | Mar 2, 2026 |
| Feb 26, 2026 | Noubar Afeyan director, owner | AGrant or award Stock Option (Right to Buy)derivative | +29,561 | $0.00 | $0 | 29,561 | Mar 2, 2026 |
| Feb 26, 2026 | Noubar Afeyan director, owner | AGrant or award Stock Option (Right to Buy)derivative | +29,561 | $0.00 | $0 | 29,561 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Series A Preferred Stockderivativeindirect: By Flagship Pioneering Fund VI, L.P. | -18,483,785 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Series A Preferred Stockderivativeindirect: By Flagship Pioneering Fund VI, L.P. | -18,483,785 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Series A Preferred Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | -17,016,215 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Series A Preferred Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | -17,016,215 | $0.00 | $0 | 0 | Mar 2, 2026 |
| Mar 2, 2026 | Noubar Afeyan director, owner | CConversion Series A Preferred Stockderivativeindirect: By Nutritional Health LTP Fund, L.P. | -1,500,000 | $0.00 | $0 | 0 | Mar 2, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Noubar Afeyandirector, owner
- Frances Arnolddirector
- Stephane Bancelceo, officer, director
- Marsha Fanuccidirector
- Gevorg GrigoryanChief Technology Officer
- Beth GrousChief People Officer
- Laurie Anne LeeChief Medical Officer
- Sean MartinChief Legal Officer & GC
- Jane L Mendillodirector
- Michael NallyChief Executive Officer
- Paul Gray Parkerdirector
- Jason SilversPresident & CFO
- Nancy A Simoniandirector
- Rupert Vesseydirector
Questions about GENB
Answered from the filings on this page, as of the latest one.
Are insiders buying GENB?
As of Sep 3, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 1 open-market sell worth $16k by 1 insider at Generate Biomedicines, Inc. in the last 90 days, net -$16k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade GENB on the open market?
Frances Arnold (director) sold $16k of GENB on Sep 1, 2026 and filed the Form 4 on Sep 3, 2026. InsiderTell scored 0 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at Generate Biomedicines, Inc.?
14 people have filed a Form 4 at Generate Biomedicines, Inc., among them Noubar Afeyan (director and 10% owner), Frances Arnold (director), Stephane Bancel (CEO and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.